Precision BioSciences, Inc.
(NASDAQ : DTIL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 7.68%161.380.0%$1898.51m
OCGNOcugen, Inc. 6.32%8.750.0%$1079.84m
BNTXBioNTech SE 6.63%192.770.0%$872.52m
AMGNAmgen, Inc. 0.43%251.381.3%$740.91m
NVAXNovavax, Inc. 8.84%131.6979.8%$572.50m
SNSSSunesis Pharmaceuticals, Inc. 0.26%7.680.7%$536.86m
GILDGilead Sciences, Inc. -0.55%68.531.0%$504.56m
REGNRegeneron Pharmaceuticals, Inc. -0.11%516.622.7%$432.65m
ALXNAlexion Pharmaceuticals, Inc. 0.09%173.492.0%$412.31m
VRTXVertex Pharmaceuticals, Inc. 1.28%217.091.9%$311.54m
ILMNIllumina, Inc. 2.03%381.033.5%$302.74m
BIIBBiogen, Inc. -0.53%280.211.7%$269.43m
VXRTVaxart, Inc. 4.92%6.610.0%$240.79m
CRSPCRISPR Therapeutics AG 5.58%106.640.6%$171.41m
BNGOBionano Genomics, Inc. 22.45%5.400.0%$162.77m

Company Profile

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.